Daichi Fujimoto

3.9k total citations
104 papers, 2.1k citations indexed

About

Daichi Fujimoto is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Daichi Fujimoto has authored 104 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Pulmonary and Respiratory Medicine, 62 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Daichi Fujimoto's work include Lung Cancer Treatments and Mutations (62 papers), Cancer Immunotherapy and Biomarkers (27 papers) and Lung Cancer Research Studies (25 papers). Daichi Fujimoto is often cited by papers focused on Lung Cancer Treatments and Mutations (62 papers), Cancer Immunotherapy and Biomarkers (27 papers) and Lung Cancer Research Studies (25 papers). Daichi Fujimoto collaborates with scholars based in Japan, United States and Spain. Daichi Fujimoto's co-authors include Keisuke Tomii, Kazuma Nagata, Atsushi Nakagawa, Kojiro Otsuka, Takeshi Morimoto, Shunsuke Teraoka, Yuki Sato, Yukihiro Imai, Munehiro Ito and Keiichiro Uehara and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Daichi Fujimoto

100 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daichi Fujimoto Japan	26	1.4k	1.4k	207	200	170	104	2.1k
İrfan Çiçin Türkiye	21	901 0.6×	1.2k 0.9×	259 1.3×	338 1.7×	188 1.1×	141	1.9k
Mehmet Alı Nahıt Şendur Türkiye	18	446 0.3×	825 0.6×	292 1.4×	160 0.8×	107 0.6×	183	1.4k
Yuichiro Takeda Japan	20	629 0.4×	780 0.6×	387 1.9×	351 1.8×	152 0.9×	123	1.6k
Koichi Kurishima Japan	19	889 0.6×	550 0.4×	313 1.5×	140 0.7×	206 1.2×	92	1.4k
Shinkichi Takamori Japan	30	1.2k 0.9×	1.7k 1.2×	256 1.2×	330 1.6×	156 0.9×	143	2.5k
Zhihuang Hu China	19	601 0.4×	1.0k 0.7×	514 2.5×	205 1.0×	140 0.8×	53	1.6k
Melissa Bersanelli Italy	19	796 0.6×	821 0.6×	479 2.3×	192 1.0×	102 0.6×	102	1.4k
Daniel Swinson United Kingdom	17	774 0.6×	562 0.4×	245 1.2×	357 1.8×	118 0.7×	45	1.4k
William J. Edenfield United States	19	741 0.5×	783 0.6×	674 3.3×	143 0.7×	158 0.9×	101	2.1k
Loı̈c Mourey France	16	882 0.6×	565 0.4×	206 1.0×	271 1.4×	59 0.3×	107	1.5k

Countries citing papers authored by Daichi Fujimoto

Since Specialization

Citations

This map shows the geographic impact of Daichi Fujimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daichi Fujimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daichi Fujimoto more than expected).

Fields of papers citing papers by Daichi Fujimoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daichi Fujimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daichi Fujimoto. The network helps show where Daichi Fujimoto may publish in the future.

Co-authorship network of co-authors of Daichi Fujimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Daichi Fujimoto. A scholar is included among the top collaborators of Daichi Fujimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daichi Fujimoto. Daichi Fujimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fujimoto, Daichi, Keishi Suzuki, Takayuki Niida, et al.. (2025). Coronary spotty calcification, compared with macro calcification, is associated with a higher level of vascular inflammation and plaque vulnerability in patients with stable angina. Atherosclerosis. 405. 119237–119237. 2 indexed citations

Kinoshita, Daisuke, Keishi Suzuki, Daichi Fujimoto, et al.. (2025). High-risk plaque features and perivascular inflammation. Journal of cardiovascular computed tomography. 19(3). 299–305. 1 indexed citations

Fujimoto, Daichi, Ryota Shibaki, Keiichi Kimura, et al.. (2025). Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning. Lung Cancer. 199. 108079–108079. 1 indexed citations

Nishio, Makoto, Shuji Murakami, Hisato Kawakami, et al.. (2024). Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer Research Communications. 4(1). 226–235. 2 indexed citations

Akamatsu, Hiroaki, Shunsuke Teraoka, Masanori Tanaka, et al.. (2023). A Phase II Study of High-Flow Nasal Cannula for Relieving Dyspnea in Advanced Cancer Patients. Journal of Pain and Symptom Management. 67(3). 204–211.e1. 3 indexed citations

Kinoshita, Daisuke, Keishi Suzuki, Haruhito Yuki, et al.. (2023). Coronary artery disease reporting and data system (CAD-RADS), vascular inflammation and plaque vulnerability. Journal of cardiovascular computed tomography. 17(6). 445–452. 6 indexed citations

Kenmotsu, Hirotsugu, Kazushige Wakuda, Keita Mori, et al.. (2022). Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study. Journal of Thoracic Oncology. 17(9). 1098–1108. 90 indexed citations

Hayashi, Hidetoshi, Shunichi Sugawara, Yasushi Fukuda, et al.. (2021). A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clinical Cancer Research. 28(5). 893–902. 49 indexed citations

Akamatsu, Hiroaki, Yuichi Ozawa, Jun Oyanagi, et al.. (2021). Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation. Anticancer Research. 41(2). 911–917. 4 indexed citations

10.

Ikesue, Hiroaki, Yoshio Masuda, Nobuyuki Muroi, et al.. (2020). Evaluation of the usefulness of protocol‐based pharmacist‐facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer. Journal of Clinical Pharmacy and Therapeutics. 45(6). 1288–1294. 7 indexed citations

11.

Kawachi, Hayato, Daichi Fujimoto, Takeshi Morimoto, et al.. (2019). Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab. Investigational New Drugs. 37(6). 1257–1265. 13 indexed citations

12.

Ito, Jiro, Kazuma Nagata, Takeshi Morimoto, et al.. (2019). Respiratory management of acute exacerbation of interstitial pneumonia using high-flow nasal cannula oxygen therapy: a single center cohort study. Journal of Thoracic Disease. 11(1). 103–112. 7 indexed citations

13.

Hosoya, Kazutaka, Daichi Fujimoto, Hayato Kawachi, et al.. (2019). Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients. Cancer Chemotherapy and Pharmacology. 84(2). 275–280. 18 indexed citations

14.

Fujimoto, Daichi, et al.. (2018). Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report. Investigational New Drugs. 36(5). 952–954. 13 indexed citations

15.

Akamatsu, Hiroaki, Yasuhiro Koh, Yuichi Ozawa, et al.. (2018). Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study. Clinical Lung Cancer. 19(6). e871–e874. 12 indexed citations

16.

Ito, Jiro, et al.. (2018). Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report. Investigational New Drugs. 36(3). 509–512. 17 indexed citations

17.

Akamatsu, Hiroaki, Yasuhiro Koh, Satoshi Morita, et al.. (2017). P3.02b-073 A Phase II, Liquid Biopsy Study Using Digital PCR in EGFR Mutated, Lung Cancer Patients Treated with Afatinib (WJOG 8114LTR). Journal of Thoracic Oncology. 12(1). S1234–S1234. 1 indexed citations

18.

Fujimoto, Daichi, Toshihide Yokoyama, Hiroshige Yoshioka, et al.. (2017). A phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). Annals of Oncology. 28. x142–x143. 4 indexed citations

19.

Fujimoto, Daichi, Takeshi Morimoto, Ryoji Kato, et al.. (2014). Analysis of advanced lung cancer patients diagnosed following emergency admission. European Respiratory Journal. 45(4). 1098–1107. 10 indexed citations

20.

Sato, Yuki, Daichi Fujimoto, Yoko Shibata, et al.. (2014). Fulminant Hepatitis Following Crizotinib Administration for ALK-positive Non-small-cell Lung Carcinoma. Japanese Journal of Clinical Oncology. 44(9). 872–875. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact